# A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colo

Source: https://onco.cc/trials/nct07506109/  
OnCo record `nct07506109` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sintilimab, cetuximab and dabrafenib in colorectal cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.

## Summary

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT07506109 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 49 participants, started 2026-03-01 and due to reach its primary completion in 2027-12. Interventions recorded: Ipilimumab N01; Sintilimab; Cetuximab; Dabrafenib. Conditions listed: BRAF V600E; Colorectal Cancer; Sintilimab; MSS (Microsatellite Stable); Cetuximab; Dabrafenib; Ipilimumab N01. Primary outcome: Progression-Free Survival (PFS). Colorectal eligibility wording from the registry: "Histologically or pathologically confirmed colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07506109
- Phase: 2
- Setting: A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT07506109: https://clinicaltrials.gov/study/NCT07506109

## Connected records

- cancers: [BRAF V600E-mutant colorectal cancer](https://onco.cc/cancers/braf-v600e-colorectal/), [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Dabrafenib](https://onco.cc/drugs/dabrafenib/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07506109.json